vWFkoncentrátumok

vWFkoncentrátumok refer to therapeutic products derived from human plasma that contain high concentrations of von Willebrand factor (vWF). These concentrates are used to treat patients with von Willebrand disease (vWD), a bleeding disorder characterized by a deficiency or dysfunction of vWF. vWF plays a crucial role in hemostasis, promoting platelet aggregation and acting as a carrier protein for coagulation factor VIII.

Treatment with vWF concentrate aims to restore normal vWF levels in the blood, thereby improving the ability of the blood to clot. This is particularly important for managing bleeding episodes, preventing excessive bleeding during surgery or dental procedures, and in some cases, for prophylaxis to reduce the frequency of spontaneous bleeds. The choice of vWF concentrate and the dosage depend on the specific type and severity of vWD, as well as the clinical situation.

There are different types of vWF concentrates available. Some contain both vWF and factor VIII (known as vWF/FVIII concentrates), as these two factors are often co-purified and used together since factor VIII is unstable without vWF. Other concentrates are designed to be primarily vWF-rich with less factor VIII activity, which may be preferred for certain patients. These products undergo rigorous manufacturing processes to ensure safety and efficacy, including viral inactivation steps. Regular monitoring of vWF levels and patient response is essential during treatment.